The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain
about
Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodiesDeaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminaseRestriction of foamy viruses by APOBEC cytidine deaminasesAdaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factorsStructural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3GHIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factorsAn extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme modelHIV-1 Vif, APOBEC, and intrinsic immunityHuman APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replicationIdentification of APOBEC3DE as another antiretroviral factor from the human APOBEC familyHuman immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integrationMultiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them allThe APOBEC3 family of retroelement restriction factorsSuppression of APOBEC3-mediated restriction of HIV-1 by VifStructural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3FRNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanismsAPOBEC3G: an intracellular centurionMultiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization.Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA.AID and Apobec3G haphazard deamination and mutational diversityThe restriction of zoonotic PERV transmission by human APOBEC3G.APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals.Deciphering Evolutionary Mechanisms Between Mutualistic and Pathogenic SymbiosesThe antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity.Selective inhibition of Alu retrotransposition by APOBEC3G.Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to VifRandom mutagenesis MAPPIT analysis identifies binding sites for Vif and Gag in both cytidine deaminase domains of Apobec3G.Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain.
P2860
Q21090536-F9B1F276-AB0F-408E-81F1-2D0FA68F37E0Q21131577-FCC76130-211D-4C8E-8519-8576EFB3C4E2Q24299944-ABD44DF3-4F97-4B1C-9CF2-AF3BC7D1C241Q24311896-2362009A-A016-46DC-ACE1-4A72402EA3EBQ24537623-F67FE6E4-0BBF-484A-B6B5-B7EF4E3688AAQ24615413-BD8173E9-F053-472F-A2D4-4801A0480C6DQ24619114-B5CABF4F-77F2-4283-B158-63C5CAA38E57Q24642268-BB1C6E2E-CF66-462F-A87B-BE87047F7989Q24647833-9E89B582-C527-4BA9-9C70-5E910D6F7A62Q24655541-D41445AF-672A-4EE4-850C-F97A0EF08AC7Q24669993-6BB00082-135E-46DB-A610-6BB5F6D5CFD3Q24670173-6D8D29FC-72EA-4F3C-BE2C-6136C306685FQ24684279-2B8ED294-B7C9-49E9-B083-3DE09E527D5FQ26823568-0992CF8D-BC22-43E0-9F93-DDB605FF65B5Q26862780-4AAE5059-3D15-4AB3-9CB2-37DB3DB2B3D9Q27025150-DCEC84BE-746D-45C3-8F8F-8FF9103BD1A8Q27680506-CEBE68B9-3854-497E-9F3F-6BCA2B552482Q28474904-5A4E2AE0-7883-47DE-B22D-442348D8C34DQ28541264-7D957336-0642-4F2C-90C4-A76BFB4BA4BCQ28754989-ABAB79F7-715E-44A3-A184-5C6FC4329F89Q30381745-A8CF5178-ACAE-4805-A314-5C03B3C6FC5BQ30445599-03FED6C5-3893-4AF0-927E-10F53A2F8737Q30483676-726E91E0-DC5A-4BF3-B572-7C6F1CE18C3FQ30525163-76305AA5-9B61-42A5-B666-EA0B22B30E78Q30537745-23856A09-24DB-4A8A-8392-D8C94CB978D2Q33298609-049894F9-B589-46F3-8E10-58395D1D4C85Q33349452-B857363C-028E-4849-96B9-510F71078FDDQ33385376-20D157F1-86BA-41B4-A5E0-AF79B0FDCFECQ33490644-D4972568-AF73-4A41-AA23-04B58BD40AE2Q33615181-D83F110F-65FE-4F22-99E3-70C14BCC1269Q33654949-9F2C48F6-6889-43D9-A9B5-763C82B38CE7Q33826968-4C5958D8-8C18-4767-9237-E232354FECF9Q33866902-EAA039CC-53D6-465A-8398-A9EF3DB9424FQ34045987-7A179AE7-7B60-4E19-BE51-61B2218C9D9BQ34048853-74C68F26-0CC0-43D3-8CA7-C9291F93825EQ34121572-25678CFF-E4D0-4804-8F0B-7C37F38694F4Q34412223-326CCBB8-6699-4CC8-B0DF-B2D7039FC8DFQ34412763-8FA565B7-BB2F-4ABE-BF1A-E28B08921118Q34651434-8DEB5939-0E80-4B7A-952B-055663782116Q34719668-16FC64FA-3CBF-40FE-9D72-20E9B919BE6E
P2860
The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
The retroviral hypermutation s ...... DNA cytosine deaminase domain
@ast
The retroviral hypermutation s ...... DNA cytosine deaminase domain
@en
The retroviral hypermutation s ...... DNA cytosine deaminase domain
@nl
type
label
The retroviral hypermutation s ...... DNA cytosine deaminase domain
@ast
The retroviral hypermutation s ...... DNA cytosine deaminase domain
@en
The retroviral hypermutation s ...... DNA cytosine deaminase domain
@nl
prefLabel
The retroviral hypermutation s ...... DNA cytosine deaminase domain
@ast
The retroviral hypermutation s ...... DNA cytosine deaminase domain
@en
The retroviral hypermutation s ...... DNA cytosine deaminase domain
@nl
P3181
P356
P1476
The retroviral hypermutation s ...... DNA cytosine deaminase domain
@en
P2093
Guylaine Haché
Mark T Liddament
P304
P3181
P356
10.1074/JBC.M500382200
P407
P577
2005-03-25T00:00:00Z